重组人血管内皮抑素联合化疗治疗转移性软组织肉瘤的临床观察

目的:探讨重组人血管内皮抑素联合化疗治疗转移性软组织肉瘤的疗效和安全性。方法:对20例诊断为晚期转移性软组织肉瘤的患者进行重组人血管内皮抑素（7.5mg/m2，静滴，连续14天，21天为一周期）联合长春瑞滨（25mg/m2，静滴，第1，8天）和顺铂（75mg/m2，静滴，分开用，第1~3天）治疗，观察临床客观缓解率，近期疾病控制率、生活质量和不良反应。结果:2008年2月至2014年5月底，共入组20例。3例（15%）获得部分缓解，16例（80%）疾病稳定，1例（5%）疾病进展。客观有效率15%，近期疾病控制率（6个月）95%，15例生活质量改善，未发生重组人血管内皮抑素相关不良反应而导致的停药事件。结论:重组人血管内皮抑素联合化疗对软组织肉瘤有较好的抗肿瘤活性，耐受性好，值得扩大样本进一步研究。

Clinical study of combined recombinant human endostatin with chemotherapy for metas-tasis soft tissue sarcoma

Objective:To expolre the efficacy and safety of recombinant human endostatin combined with chemotherapy in the treatment of metastasis soft tissue sarcoma.Methods:Twenty patients with pathologically confirmed metastasis soft tissue sarcoma received combined endostar (7.5mg/m2，d1~14，21d as a cycle) with vinorelbine (25mg/m2，d1，8) and cisplatinum(75mg/m2，d1~3).The clinical objective remission rate，disease control rate，quality of life (QOL) and adverse event were observed.Results:From 2008 February to 2014 May，20 cases were enrolled.3 cases achieved partial remission(15%)，16 cases stable disease(80%)，1 case emerged disease progression(5%).The objective remission rate was 15%，the disease control rate was 95%.15 patients QOL were improved.The adverse event related endostar caused stop treatment was not happened.Conclusion:Combined endostar with chemotherapy in treatment of metastasis soft tissue sarcoma could control disease progression with well tolerance.More subjects shoule be enrolled for futher study.